Researchers behind the ASPIRE trial want to take the drug even further. Their new goal is to have the drug approved to treat patients with major depressive disorder who have active suicidal ideation with intent.
“Ketamine was actually restoring many of the exact same synapses in their exact same configuration that existed before the animal was exposed to chronic stress,” he says.
In other words, the drug seemed to be repairing brain circuits that had been damaged by stress.
The FDA approved a new ketamine depression drug — here’s what’s next
An excellent piece by Dr. Sanjay Gupta outlining the benefits of ketamine infusions for depression.
A local news piece provides an overview of ketamine for depression
“I think it’s actually one of the biggest advances in psychiatry in a very long time,” says Dr. Martin Teicher, an associate professor of psychiatry at Harvard Medical School and director of the Developmental Biopsychiatry Research Program at McLean Hospital.
Gerard Sanacora, a professor of psychiatry at Yale University, has treated hundreds of severely depressed patients with low doses of ketamine, an anesthetic and popular club drug that isn’t approved for depression…